Skip to content

A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor

A Combination of Antibiotics to Decrease Neonatal Mortality and Morbidity for Pregnancies Complicated With Previable Labour and Intact Membranes: a Multicenter, Open-label, Randomized and Controlled Trial

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06572761
Acronym
ECHEC-MAT
Enrollment
350
Registered
2024-08-27
Start date
2026-09-01
Completion date
2030-05-01
Last updated
2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previable Labour With Intact Membranes

Keywords

previable labour, preterm

Brief summary

The purpose of this study is to determine whether a combination of antibiotics (cephalosporin 3rd generation, clarithromycin, metronidazole) are effective to prolong pregnancies complicated with previable threatened labour with intact membranes.

Detailed description

Observational data suggest that subclinical infectious conditions can lead to spontaneous preterm labor. 10% of births are premature, but the morbidity/mortality of premature babies is concentrated mainly among newborns born before 30 weeks of gestation or weighing less than 1500 g. The relationship to infection/inflammation and premature birth is not constant throughout pregnancy, but this infectious risk increases the earlier the gestational age of spontaneous labor is (before 30 weeks). The pathogens that have the strongest associations with premature birth are Gardnerella vaginalis, Ureaplasma urealyticum and Mycoplasma hominis, but also Streptococcus B, Escherichia coli, Klebsiella spp, or Haemophilus influenzae. Antibiotic treatment to treat an intra-amniotic infection is considered ineffective. Indeed, the last randomized trial (Oracle 2, 2001), which studied several antibiotic regimens for threatened premature delivery with intact membranes, did not find a significant reduction in neonatal morbidity/mortality after administration of co-beta-lactam, erythromycin or the combination of both. In addition, this large trial dominates the results of the latest Cochrane meta-analysis which evaluated preventive antibiotic therapy to stop premature labor with intact membranes. Recently, it has been showed that a new combination of antibiotics (ceftriaxone, clarithromycin and metronidazole) reduced the risk of infection and intra-amniotic inflammation in preterm labor with intact membranes. This retrospective study deserves to be confirmed by a randomized study The investigator's goal is to study whether a new combination of antibiotics in a very limited population of pregnancies complicated by the threat of late miscarriage would make it possible to prolong pregnancies in order to improve neonatal outcomes.

Interventions

DRUGCombination of antibiotics

Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally

DEVICEEmergency cerclage

Emergency cerclage

DRUGVaginal progesterone

Vaginal progesterone

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Threatened previable prelabor with intact membranes between 18weeks of gestation +0/7 and 23 weeks of gestation 6/7 SA defined on endovaginal ultrasound by a short cervix ≤10 mm, and/or protrusion of the membranes on speculum examination. * Maternal age \>18 years * Affiliated with social security * Correct understanding of the French language * Singleton pregnancy * Foetus alive at time of inclusion * Absence of regular and painful uterine contractions

Exclusion criteria

* Premature labor defined by regular, painful uterine contractions and a short cervix * Protected person (patient under guardianship/curatorship/or legal protection) * Multiple pregnancies * Premature rupture of membranes * Acute chorioamnionitis * Contraindication to protocol antibiotics * Chromosomal abnormality, congenital malformation * Patients who received antibiotics before randomization, or requiring antibiotics for another indication (chorioamnionitis, pyelonephritis, etc.) * Participation in another research (Specify the category: RIPH, EC, IC, etc.) or being in the exclusion period following previous research involving humans, if applicable * Patient under AME (if no exemption from affiliation)

Design outcomes

Primary

MeasureTime frameDescription
A perinatal composite outcomeUp to 24 weeks* Late miscarriage * Perinatal mortality * Bronchodysplasia, * Sepsis proven by blood culture, * Intraventricular hemorrhage ≥3, * Periventricular leukomalacia ≥2, * Ulcero-necrotizing enterocolitis at stage ≥2 according to the Bell classification.

Secondary

MeasureTime frameDescription
Gestationnal age at delivery6 months* Gestationnal age at delivery ≥ 24 weeks of gestation (wg) 0/7, 28 wg0/7, 32 wg0/7, 34 wg0/7 et 37 wg0/7 * Latency period between randomisation and delivery (≥2 days, ≥7 days, ≥14 days et ≥28 days)
Maternal Morbidty6 monthsChorioamniotitis, postpartum endometritis , sepsis proven par positive hemocultures
Bacteriological6 monthsAcquisition of multi-resistant germs during childbirth

Countries

France

Contacts

CONTACTThibaud QUIBEL, MD, PhD
thibaud.quibel@ght-yvelinesnord.fr0178636012
CONTACTCharly LARRIEU
charly.larrieu@aphp.fr01 58 41 34 78
PRINCIPAL_INVESTIGATORThibaud QUIBEL, MD, PhD

Centre Hospitalier Poissy-Saint Germain

STUDY_CHAIRJean BOUYER

Institut National de la Santé Et de la Recherche Médicale, France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026